Annovis Bio Inc. provided corporate updates on August 12, 2025, highlighting significant progress in its pivotal Phase 3 trial for early Alzheimer's disease (AD). The company reported that its efforts in the past quarter were centered on driving enrollment for this trial. The study now includes 76 secured clinical sites across the U.S.
The company also announced that over 400 patients have been screened to date for the trial. This demonstrates concrete operational advancement in the execution of the critical late-stage study. Maria Maccecchini, Ph.D., CEO of Annovis, stated that the focus remains firmly on completing enrollment as planned to produce strong and trustworthy results.
This progress is crucial for the timely completion of the trial and for advancing buntanetap towards potential market approval. The company also mentioned advancing its Parkinson’s program, with more updates expected as progress continues.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.